Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

6(75.0%)

Phase 2

1(12.5%)

Phase 3

1(12.5%)

8Total

Phase 1(6)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05543330Phase 1Recruiting

A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC

Role: lead

NCT04501770Phase 1Completed

A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors

Role: lead

NCT05011097Phase 1Completed

A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

Role: lead

NCT06432296Phase 3Active Not Recruiting

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Role: lead

NCT06266091Phase 2Completed

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Role: lead

NCT06266143Phase 1Active Not Recruiting

A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer

Role: lead

NCT05028556Phase 1Completed

A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors

Role: lead

NCT04501744Phase 1Completed

A Study of M701 (EpCAM and CD3) in Malignant Ascites

Role: lead

All 8 trials loaded